<DOC>
	<DOCNO>NCT01676948</DOCNO>
	<brief_summary>This two-part open-label , multi-arm , non-comparative study collect long-term safety , efficacy tolerability data patient responsive canakinumab study CACZ885G2301E1 ( Cohort 1 ) , patient treatment naïve canakinumab ( Cohort 2 ) . In addition , effect inactivate vaccine SJIA patient population assess development adequate ( protective ) antibody level follow immunization accord respective local vaccination guideline . Study Part I : All patient treat canakinumab 4 mg/kg every 4 week ( 2 mg/kg every 4 week Cohort 1 patient receive dose CACZ885G2301E1 ) study end unless discontinuation occurs , qualify Part II study . Study Part II : Patients eligible randomized receive canakinumab reduce dose prolong dose interval ( see requirement dose reduction/dose interval prolongation ) . Patients Cohort 1 receive 2 mg/kg q4wk CACZ885G2301E1 randomize part treatment arm canakinumab dose reduction eligible .</brief_summary>
	<brief_title>An Open-label , Multi-arm , Non-comparative Safety Tolerability Study Canakinumab ( ACZ885 ) Patients With Active Systemic Juvenile Idiopathic Arthritis ( SJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key inclusion criterion : Cohort 1 : 1 . All patient currently enrol study CACZ885G2301E1 , include patient discontinue canakinumab therapy inactive disease CACZ885G2301E1 per physician discretion currently flare require canakinumab therapy Cohort 2 : 1 . Male female patient age ≥ 2 &lt; 20 year time screen visit 2 . Confirmed diagnosis SJIA per ILAR definition must occur least 2 month prior enrollment onset disease &lt; 16 year age : • Arthritis one joint , precede fever least 2 week duration document daily/quotidian least 3 day accompany one following : Evanescent nonfixed erythematous rash , Generalized lymph node enlargement , Hepatomegaly and/ splenomegaly , Serositis 3 . Active systemic disease time baseline visit define 2 following : Documented spiking , intermittent fever ( body temperature &gt; 38°C ) least 1 day screen period within 1 week first canakinumab dose , At least 2 joint active arthritis ( use ACR definition active joint ) , Creactive protein ( CRP ) &gt; 30 mg/L ( normal range &lt; 10 mg/L ) , Rash , Serositis , Lymphadenopathy , Hepatosplenomegaly 4 . Patient 's willingness discontinue anakinra , rilonacept , tocilizumab experimental drug close monitoring 5 . Patients schedule receive immunization , accord local vaccination guideline , inactivated vaccine willing participate assessment schedule vaccinate patient Key exclusion criterion : Cohort 1 Cohort 2 : 1 . Active recurrent bacterial , fungal viral infection time enrollment 2 . Underlying metabolic , renal , hepatic , infectious gastrointestinal condition opinion investigator immunocompromises patient and/ place patient unacceptable risk participation immunomodulatory therapy . 3 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 4 . Live vaccination within 3 month prior start study . Cohort 2 : The follow additional key exclusion criterion apply Cohort 2 . 1 . Presence moderate severe impaired renal function 2 . Clinical evidence liver disease liver injury indicate abnormal liver function test screen 3 . History/evidence macrophage activation syndrome within previous 6 month Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>SJIA</keyword>
	<keyword>Systemic Juvenile Idiopathic Arthritis</keyword>
	<keyword>child</keyword>
	<keyword>systemic autoinflammatory disease , ACZ885 , canakinumab</keyword>
	<keyword>human monoclonal anti-interleukin-1β ( IL-1 β ) antibody</keyword>
	<keyword>hildhood immunization vaccination</keyword>
</DOC>